Filtered By:
Drug: Docetaxel
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 2210 results found since Jan 2013.
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer
CONCLUSION: A subset of patients (10%) receiving trastuzumab in the metastatic setting have achieved long-term survival beyond 20 years.PMID:37725049 | DOI:10.1093/oncolo/oyad258
Source: The Oncologist - September 19, 2023 Category: Cancer & Oncology Authors: Juan Luis Gomez Marti Azadeh Nasrazadani Ying Ding Daniel Normolle Adam M Brufsky Source Type: research
In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
Conclusions TNBC is a difficult-to-treat oncologic condition, even in an experimental setting. Promising results concerning the addition of targeted therapies (dasatinib) to the conventional cytotoxic ones (docetaxel) have been shown, awaiting further evaluation.PMID:37719631 | PMC:PMC10500968 | DOI:10.7759/cureus.43534
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Ioannis D Passos Dimochristos Papadimitriou Areti Katsouda Georgios E Papavasileiou Apostolos Galatas Panagiotis Tzitzis Alexandra Mpakosi Maria Mironidou-Tzouveleki Source Type: research
The effects of pretreatment with Cyclosporin A and Docetaxel before vitrification of porcine immature oocytes on subsequent embryo development
In conclusion, vitrification reduced mitochondrial activity in GV-stage oocytes during 0-22 h of IVM; however, it was normalized by 46 h IVM. Docetaxel or CsA pretreatment alone did not improve development competence of vitrified oocytes. However, pretreatment with a combination of CsA and Docetaxel could improve blastocyst formation rates.PMID:37717489 | DOI:10.1016/j.repbio.2023.100798
Source: Reproductive Biology - September 17, 2023 Category: Reproduction Medicine Authors: Hong Thi Nguyen Nhung Thi Nguyen Linh Viet Nguyen Xuan Nguyen Bui Van Hanh Nguyen Van Khanh Nguyen Huong Thu Thi Vu Sam Thi Nguyen Hiep Thi Nguyen Source Type: research
A novel self-assembled nanoplatform based on retrofitting poloxamer 188 for triple-negative breast cancer targeting treatment
In this study, a novel self-assembled nanoplatform was developed for active targeting of folate receptor-overexpressing triple-negative breast cancer. This platform, FPP NPs, was prepared by the retrofitted poloxamer 188 derivatives, resulting in nanoparticles with an appropriate size (<100 nm), good stability, and satisfactory biocompatibility. Cellular uptake and in vivo distribution studies showed that the FPP NPs had strong tumor cell uptake and active targeting capabilities. Furthermore, docetaxel (DTX) was loaded into FPP NPs in this research. The resulting DTX/FPP NPs exhibited high drug encapsulation efficiency ...
Source: Chemico-Biological Interactions - September 16, 2023 Category: Molecular Biology Authors: Xueyan Hou Yalin Guan Sisi He Zeqing Wu Jintao Bai Jingjing Xu Jingwen Wang Suyue Xu Huiqing Zhu Yanyan Yin Xue Yang Yongli Shi Source Type: research
Ki67 and prostate specific antigen are prognostic in metastatic hormone na ïve prostate cancer
CONCLUSION: PSA and Ki67 immunoreactive scores are prognostic in the metastatic hormone-sensitive setting, with PSA being superior. The combination of Ki67 and PSA did not give additional prognostic value. The results suggest immunohistochemical scoring of PSA to have potential to improve identification of patients responding well to ADT alone.PMID:37713321 | DOI:10.1080/0284186X.2023.2254480
Source: Acta Oncologica - September 15, 2023 Category: Cancer & Oncology Authors: Vasiliki Spyratou Eva Freyhult Anders Bergh Camilla Thellenberg-Karlsson Pernilla Wikstr öm Karin Wel én Andreas Josefsson Source Type: research
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
This study is registered with ClinicalTrials.gov, NCT03732820, and is completed and no longer recruiting.FINDINGS: Between Oct 31, 2018 and March 11, 2020, 1103 patients were screened, of whom 399 were randomly assigned to olaparib plus abiraterone and 397 to placebo plus abiraterone. Median follow-up for overall survival in patients with censored data was 36·6 months (IQR 34·1-40·3) for olaparib plus abiraterone and 36·5 months (33·8-40·3) for placebo plus abiraterone. Median overall survival was 42·1 months (95% CI 38·4-not reached) with olaparib plus abiraterone and 34·7 months (31·0-39·3) with placebo plus a...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Fred Saad Noel W Clarke Mototsugu Oya Neal Shore Giuseppe Procopio Jo ão Daniel Guedes Cagatay Arslan Niven Mehra Francis Parnis Emma Brown Friederike Schl ürmann Jae Young Joung Mikio Sugimoto Oliver Sartor Yu-Zhen Liu Christian Poehlein Laura Barker P Source Type: research
Ki67 and prostate specific antigen are prognostic in metastatic hormone na ïve prostate cancer
CONCLUSION: PSA and Ki67 immunoreactive scores are prognostic in the metastatic hormone-sensitive setting, with PSA being superior. The combination of Ki67 and PSA did not give additional prognostic value. The results suggest immunohistochemical scoring of PSA to have potential to improve identification of patients responding well to ADT alone.PMID:37713321 | DOI:10.1080/0284186X.2023.2254480
Source: Acta Oncologica - September 15, 2023 Category: Cancer & Oncology Authors: Vasiliki Spyratou Eva Freyhult Anders Bergh Camilla Thellenberg-Karlsson Pernilla Wikstr öm Karin Wel én Andreas Josefsson Source Type: research
Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis
CONCLUSIONS: Neoadjuvant DCS therapy for resectable advanced ESCC did not result in significantly higher clinical and pathological response than neoadjuvant DCF therapy. However, neoadjuvant DCS therapy for resectable ESCC required comparatively shorter hospital stays and incurred lower costs, making it an attractive therapeutic option.PMID:37708864 | DOI:10.1159/000533790
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Junya Kitadani Toshiyasu Ojima Keiji Hayata Taro Goda Akihiro Takeuchi Shinta Tominaga Naoki Fukuda Tomoki Nakai Hiroki Yamaue Manabu Kawai Source Type: research
Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1
CONCLUSION: In HLA-A2 positive patients with advanced NSCLC and secondary resistance to immunotherapy, OSE2101 increased survival with better safety compared to chemotherapy. Further evaluation in this population is warranted.PMID:37704166 | DOI:10.1016/j.annonc.2023.07.006
Source: Ann Oncol - September 13, 2023 Category: Cancer & Oncology Authors: B Besse E Felip R Garcia Campelo M Cobo C Mascaux A Madroszyk F Cappuzzo W Hilgers G Romano F Denis S Viteri D Debieuvre D Galetta E Baldini None M Razaq G Robinet M Maio A Delmonte B Roch P Masson W Schuette A Zer J Remon D Costantini B Vasseur R Dziadzi Source Type: research
